Harry H. Yoon
Mayo Clinic(US)Mayo Clinic in Arizona(US)Mayo Clinic in Florida(US)
Publications by Year
Research Areas
Gastric Cancer Management and Outcomes, Esophageal Cancer Research and Treatment, Cancer Immunotherapy and Biomarkers, Gastrointestinal Tumor Research and Treatment, Genetic factors in colorectal cancer
Most-Cited Works
- → Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer(2018)1,796 cited
- → Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology(2022)1,640 cited
- → Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology(2023)466 cited
- → Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability–High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials(2021)424 cited
- → Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study(2023)267 cited
- → Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study